ICU Medical, Inc. (NASDAQ:ICUI) Shares Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP raised its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 199.4% during the third quarter, HoldingsChannel reports. The institutional investor owned 7,808 shares of the medical instruments supplier’s stock after acquiring an additional 5,200 shares during the quarter. GSA Capital Partners LLP’s holdings in ICU Medical were worth $1,423,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of ICUI. BNP Paribas Financial Markets boosted its position in ICU Medical by 55.3% during the 1st quarter. BNP Paribas Financial Markets now owns 4,552 shares of the medical instruments supplier’s stock worth $489,000 after purchasing an additional 1,620 shares during the period. Texas Permanent School Fund Corp boosted its position in shares of ICU Medical by 1.4% in the first quarter. Texas Permanent School Fund Corp now owns 17,708 shares of the medical instruments supplier’s stock worth $1,900,000 after buying an additional 243 shares during the period. Sei Investments Co. grew its stake in shares of ICU Medical by 52.1% in the first quarter. Sei Investments Co. now owns 28,586 shares of the medical instruments supplier’s stock valued at $3,068,000 after buying an additional 9,793 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of ICU Medical by 46.4% in the first quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock valued at $59,000 after buying an additional 173 shares in the last quarter. Finally, US Bancorp DE raised its holdings in shares of ICU Medical by 18.2% during the 1st quarter. US Bancorp DE now owns 3,098 shares of the medical instruments supplier’s stock valued at $332,000 after buying an additional 476 shares during the period. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the transaction, the vice president now directly owns 13,107 shares in the company, valued at approximately $2,139,324.54. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the transaction, the vice president now owns 13,107 shares of the company’s stock, valued at $2,139,324.54. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total value of $2,141,520.00. Following the completion of the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $18,665,666.78. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,502 shares of company stock valued at $8,445,976 over the last 90 days. 6.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on ICUI. StockNews.com downgraded shares of ICU Medical from a “buy” rating to a “hold” rating in a research report on Tuesday. KeyCorp raised their price target on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday. Jefferies Financial Group began coverage on shares of ICU Medical in a report on Monday, October 14th. They issued a “hold” rating and a $183.00 price objective on the stock. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research note on Wednesday. Finally, Raymond James boosted their price target on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $173.00.

ICU Medical Price Performance

ICUI opened at $174.81 on Thursday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. ICU Medical, Inc. has a 1-year low of $82.82 and a 1-year high of $196.26. The company has a 50-day moving average of $176.11 and a 200-day moving average of $141.98. The company has a market capitalization of $4.27 billion, a P/E ratio of -38.25 and a beta of 0.66.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Tuesday, November 12th. The medical instruments supplier reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.35. The firm had revenue of $580.07 million for the quarter, compared to analysts’ expectations of $574.77 million. ICU Medical had a positive return on equity of 5.04% and a negative net margin of 4.74%. Equities analysts expect that ICU Medical, Inc. will post 3.81 EPS for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.